The Technical AnalystExchange: STO Sector: Healthcare Industry: Biotechnology
IRLAB Therapeutics AB Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.39% SEK15.25
America/New_York / 17 mai 2024 @ 11:29
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 789.78 mill |
| EPS: | -3.43 |
| P/E: | -4.45 |
| Earnings Date: | Jul 10, 2024 |
| SharesOutstanding: | 51.79 mill |
| Avg Daily Volume: | 0.0769 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.45 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -4.45 | industry: PE 491.84 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK-2.18 (-114.31%) SEK-17.43 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 14.10 - 16.40 ( +/- 7.53%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK15.25 (3.39% ) |
| Volume | 0.100 mill |
| Avg. Vol. | 0.0769 mill |
| % of Avg. Vol | 130.29 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IRLAB-A.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IRLAB-A.ST
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.